Nasser A Dhayat1, Andrea C Frey2, Brigitte M Frey3, Claudia H d'Uscio4, Bruno Vogt5, Valentin Rousson6, Bernhard Dick7, Christa E Flück8. 1. Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: nasser.dhayat@insel.ch. 2. Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: andrea.frey@hispeed.ch. 3. Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: brigitte.frey@dkf.unibe.ch. 4. Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: claudia.d'uscio@insel.ch. 5. Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: bruno.vogt@insel.ch. 6. Division of Biostatistics, Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Biopôle 2, Route de la Corniche 10, 1010 Lausanne, Switzerland. Electronic address: valentin.rousson@chuv.ch. 7. Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: bernhard.dick@insel.ch. 8. Department of Pediatrics (Pediatric Endocrinology and Diabetology, University Children's Hospital) and Department of Clinical Research, University of Bern, Freiburgstrasse 15, 3010, Switzerland. Electronic address: christa.flueck@dkf.unibe.ch.
Abstract
CONTEXT: Complex steroid disorders such as P450 oxidoreductase deficiency or apparent cortisone reductase deficiency may be recognized by steroid profiling using chromatographic mass spectrometric methods. These methods are highly specific and sensitive, and provide a complete spectrum of steroid metabolites in a single measurement of one sample which makes them superior to immunoassays. The steroid metabolome during the fetal-neonatal transition is characterized by (a) the metabolites of the fetal-placental unit at birth, (b) the fetal adrenal androgens until its involution 3-6 months postnatally, and (c) the steroid metabolites produced by the developing endocrine organs. All these developmental events change the steroid metabolome in an age- and sex-dependent manner during the first year of life. OBJECTIVE: The aim of this study was to provide normative values for the urinary steroid metabolome of healthy newborns at short time intervals in the first year of life. METHODS: We conducted a prospective, longitudinal study to measure 67 urinary steroid metabolites in 21 male and 22 female term healthy newborn infants at 13 time-points from week 1 to week 49 of life. Urine samples were collected from newborn infants before discharge from hospital and from healthy infants at home. Steroid metabolites were measured by gas chromatography-mass spectrometry (GC-MS) and steroid concentrations corrected for urinary creatinine excretion were calculated. RESULTS: 61 steroids showed age and 15 steroids sex specificity. Highest urinary steroid concentrations were found in both sexes for progesterone derivatives, in particular 20α-DH-5α-DH-progesterone, and for highly polar 6α-hydroxylated glucocorticoids. The steroids peaked at week 3 and decreased by ∼80% at week 25 in both sexes. The decline of progestins, androgens and estrogens was more pronounced than of glucocorticoids whereas the excretion of corticosterone and its metabolites and of mineralocorticoids remained constant during the first year of life. CONCLUSION: The urinary steroid profile changes dramatically during the first year of life and correlates with the physiologic developmental changes during the fetal-neonatal transition. Thus detailed normative data during this time period permit the use of steroid profiling as a powerful diagnostic tool.
CONTEXT: Complex steroid disorders such as P450 oxidoreductase deficiency or apparent cortisone reductase deficiency may be recognized by steroid profiling using chromatographic mass spectrometric methods. These methods are highly specific and sensitive, and provide a complete spectrum of steroid metabolites in a single measurement of one sample which makes them superior to immunoassays. The steroid metabolome during the fetal-neonatal transition is characterized by (a) the metabolites of the fetal-placental unit at birth, (b) the fetal adrenal androgens until its involution 3-6 months postnatally, and (c) the steroid metabolites produced by the developing endocrine organs. All these developmental events change the steroid metabolome in an age- and sex-dependent manner during the first year of life. OBJECTIVE: The aim of this study was to provide normative values for the urinary steroid metabolome of healthy newborns at short time intervals in the first year of life. METHODS: We conducted a prospective, longitudinal study to measure 67 urinary steroid metabolites in 21 male and 22 female term healthy newborn infants at 13 time-points from week 1 to week 49 of life. Urine samples were collected from newborn infants before discharge from hospital and from healthy infants at home. Steroid metabolites were measured by gas chromatography-mass spectrometry (GC-MS) and steroid concentrations corrected for urinary creatinine excretion were calculated. RESULTS: 61 steroids showed age and 15 steroids sex specificity. Highest urinary steroid concentrations were found in both sexes for progesterone derivatives, in particular 20α-DH-5α-DH-progesterone, and for highly polar 6α-hydroxylated glucocorticoids. The steroids peaked at week 3 and decreased by ∼80% at week 25 in both sexes. The decline of progestins, androgens and estrogens was more pronounced than of glucocorticoids whereas the excretion of corticosterone and its metabolites and of mineralocorticoids remained constant during the first year of life. CONCLUSION: The urinary steroid profile changes dramatically during the first year of life and correlates with the physiologic developmental changes during the fetal-neonatal transition. Thus detailed normative data during this time period permit the use of steroid profiling as a powerful diagnostic tool.
Authors: Matthias B Moor; Nasser A Dhayat; Simeon Schietzel; Michael Grössl; Bruno Vogt; Daniel G Fuster Journal: Urolithiasis Date: 2022-02-24 Impact factor: 2.861
Authors: Andreas Kyriakou; Arianne Dessens; Jillian Bryce; Violeta Iotova; Anders Juul; Maciej Krawczynski; Agneta Nordenskjöld; Marta Rozas; Caroline Sanders; Olaf Hiort; S Faisal Ahmed Journal: Orphanet J Rare Dis Date: 2016-11-21 Impact factor: 4.123
Authors: Daniel Ackermann; Michael Groessl; Menno Pruijm; Belen Ponte; Geneviève Escher; Claudia H d'Uscio; Idris Guessous; Georg Ehret; Antoinette Pechère-Bertschi; Pierre-Yves Martin; Michel Burnier; Bernhard Dick; Bruno Vogt; Murielle Bochud; Valentin Rousson; Nasser A Dhayat Journal: PLoS One Date: 2019-03-29 Impact factor: 3.240
Authors: Valentin Rousson; Daniel Ackermann; Belen Ponte; Menno Pruijm; Idris Guessous; Claudia H d'Uscio; Georg Ehret; Geneviève Escher; Antoinette Pechère-Bertschi; Michael Groessl; Pierre-Yves Martin; Michel Burnier; Bernhard Dick; Murielle Bochud; Bruno Vogt; Nasser A Dhayat Journal: PLoS One Date: 2021-07-08 Impact factor: 3.240
Authors: Nasser A Dhayat; Nesa Marti; Zahraa Kollmann; Amineh Troendle; Lia Bally; Geneviève Escher; Michael Grössl; Daniel Ackermann; Belen Ponte; Menno Pruijm; Michael Müller; Bruno Vogt; Martin H Birkhäuser; Murielle Bochud; Christa E Flück Journal: PLoS One Date: 2018-10-11 Impact factor: 3.240